T regulatory cells in cancer: recent advances and therapeutic potential.
about
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic TargetingNeem components as potential agents for cancer prevention and treatmentThe role of regulatory T cells in cancer immunologyRole of vaccine therapy for renal cell carcinoma in the era of targeted therapyCD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interestInterleukin-27 signaling promotes immunity against endogenously arising murine tumors.Functions of thymic stromal lymphopoietin in immunity and disease.Helios, and not FoxP3, is the marker of activated Tregs expressing GARP/LAP.TLR2 ligation protects effector T cells from regulatory T-cell mediated suppression and repolarizes T helper responses following MVA-based cancer immunotherapy.Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effectsImmunomodulatory effects of total intravenous and balanced inhalation anesthesia in patients with bladder cancer undergoing elective radical cystectomy: preliminary results.Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients.Peripheral and thymic foxp3(+) regulatory T cells in search of origin, distinction, and functionThe effect of metronomic versus standard chemotherapy on the regulatory to effector T-cell equilibrium in cancer patients.Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer.Natural and induced T regulatory cells in cancer.Clinical evaluation of systemic and local immune responses in cancer: time for integration.Neuropilin 1: function and therapeutic potential in cancer.Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer.Induced regulatory T cells in inhibitory microenvironments created by cancer.Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV.Silencing IDO in dendritic cells: a novel approach to enhance cancer immunotherapy in a murine breast cancer model.Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma.Helios Should Not Be Cited as a Marker of Human Thymus-Derived Tregs. Commentary: Helios(+) and Helios(-) Cells Coexist within the Natural FOXP3(+) T Regulatory Cell Subset in Humans.FOXP3+ regulatory T cells in normal prostate tissue, postatrophic hyperplasia, prostatic intraepithelial neoplasia, and tumor histological lesions in men with and without prostate cancer.T-Cell Immunopeptidomes Reveal Cell Subtype Surface Markers Derived From Intracellular Proteins.Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma.Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination.Analyses of 123 Peripheral Human Immune Cell Subsets: Defining Differences with Age and between Healthy Donors and Cancer Patients Not Detected in Analysis of Standard Immune Cell Types.Interleukin-17 facilitates the immune suppressor capacity of high-grade glioma-derived CD4 (+) CD25 (+) Foxp3 (+) T cells via releasing transforming growth factor beta.Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report
P2860
Q26742012-69FF49B3-2F18-4E09-AFD5-8A9BB5A0DA65Q26995699-043892FF-CD6A-450A-902E-35FD5C1E76F0Q27006663-1E7B90EE-2668-4745-BC7C-98B135530E2AQ27016032-50DF1A26-C6CA-421E-964C-151BE95DB77AQ28270624-237027DB-A8B1-4D31-8E99-EE7BE825FB66Q34647840-EEFF98DF-C28A-4E35-B9C4-42979731F6ACQ35953900-7E2E80E8-56D6-4EBD-8BBD-A728E94C2B42Q36299565-8E4B09CC-84F6-4209-9004-BBD383C2618AQ36456469-89081DFF-402D-41ED-9BE8-35713F479F4BQ36610868-0C85A528-3C6F-4190-B257-2C4AA21C5D39Q36624367-D2AB6997-C44C-472B-86C8-66730B056570Q36821572-A83341AE-EA09-4A00-9201-7DD01C929A0DQ37046528-564CB2F7-13AD-40FD-B236-BE1119ABBB1CQ37122171-4BA9C200-1255-471E-82CB-8774DFD4EF23Q37531844-946F1959-F6E2-4AEC-B471-462367CA835DQ37670024-A0058A0A-5BF7-49C5-A04C-5700989BBD36Q37711669-7ADB1DAB-BD3C-4640-9010-FC1583F33985Q38123165-98680081-7A96-4EE8-88FB-62A8DE5F911DQ38150174-E01550DD-00E2-40E6-875C-A93F87E59B55Q38165001-36CDF934-C7D5-42ED-BAA1-BD223B51FBD8Q38198735-0FD0C33C-8D54-456D-B6A1-211266F60BE3Q38220701-CAD3BF09-63DA-4D0C-858C-F0686014D643Q38266807-C58E3103-5E2B-4DB2-BE42-C80EEFEC78FDQ39301153-1FEAE726-E592-4B60-AAFE-CA46392B05EBQ39514618-44835DA6-F359-4AFC-9C21-13D988C95DDCQ39561722-DF03E226-3719-4009-9131-DBAB53358F19Q47112373-2EBF92D2-FC49-4755-982C-264962BA7A8FQ52680130-E151195B-ABAD-435F-9EC9-B0E23B5EA519Q53110291-04E94699-9D7A-400E-B85B-6B5E457B7DF2Q54238337-AE47D022-EE9C-4D5E-B073-BC7A98EA6D61Q54511300-FC5E6277-E68A-45A0-9592-1E73019698AAQ55460935-5653E70F-252F-4AB9-AE41-C74387AD3CCCQ58737851-28F1C091-D7BD-453E-AEB3-3D2CF9F35EE8
P2860
T regulatory cells in cancer: recent advances and therapeutic potential.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
T regulatory cells in cancer: recent advances and therapeutic potential.
@en
T regulatory cells in cancer: recent advances and therapeutic potential.
@nl
type
label
T regulatory cells in cancer: recent advances and therapeutic potential.
@en
T regulatory cells in cancer: recent advances and therapeutic potential.
@nl
prefLabel
T regulatory cells in cancer: recent advances and therapeutic potential.
@en
T regulatory cells in cancer: recent advances and therapeutic potential.
@nl
P2093
P2860
P1476
T regulatory cells in cancer: recent advances and therapeutic potential.
@en
P2093
Dat Q Tran
David E Gilham
Erik M Alcantar-Orozco
Eyad Elkord
Robert E Hawkins
Simon J Dovedi
P2860
P304
P356
10.1517/14712598.2010.529126
P407
P577
2010-11-01T00:00:00Z